Acquisition Pending

Gyre Therapeutics acquisition of Cullgen

US$300m equity value

Announced 2 Mar 2026

Advisers

Cullgen

Target

Legal adviser

Gyre Therapeutics

Acquirer

Financial adviser
Legal adviser
Target
Cullgen
Acquirer
Gyre Therapeutics
Target based in
United States (unverified)
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.